The role of the High Throughput Screening (HTS) platform is to identify hits or tool compounds for EDDC’s projects. The HTS group had screened and identified many precursor compounds that were successfully developed into preclinical candidates (PDCs) by EDDC, and some have been successfully out-licensed.
This is done by screening compound libraries, ranging from small focus sets to large diverse collection of more than 350,000 curated compounds. EDDC’s HTS utilises a fully integrated automation platform to achieve a fast turnaround time, allowing the screening of up to 16,000 compounds per day per project.
The group is experienced in conducting biochemical & functional cell-based assays with various assay readouts – absorbance, fluorescence, fluorescence polarisation, luminescence, FRET, nanoBRET, etc.
Screens previously performed:
- Biochemical (Kinases, Proteases, Methyltransferase, protein-protein interactions)
- Signal transduction/Receptor (GPCR, Potassium Channel, et.)
- Anti-infectives (virus, bacteria)
- Cell-based assays (Wnt pathway, nano-BRET, protein degradation, etc.)
This capability is available on a fee-for-service basis through EARO. For more on the service aspects of the platform, please refer to EARO-HTS.